Navigation Links
MEI Pharma Initiates Phase II Clinical Trial Of Pracinostat In Refractory Myelodysplastic Syndrome
Date:1/14/2014

ts per group. Preliminary data from this open-label trial is anticipated by December 2014.

The primary endpoint of the trial is clinical improvement rate, defined as the proportion of patients with complete remission (CR), partial remission (PR) and hematologic improvement (HI). Secondary endpoints include overall response rate, CR rate, HI rate, duration of response, progression-free survival, time to progression and overall survival. Dr. Guillermo Garcia-Manero of the MD Anderson Cancer Center is the study's Principal Investigator. Additional information regarding the trial is available at www.clinicaltrials.gov.

Meanwhile, MEI Pharma remains on track to fully enroll its randomized, placebo-controlled Phase II trial of Pracinostat in combination with Vidaza in patients with previously untreated intermediate-2 or high-risk MDS by June 2014, with topline data expected by December 2014.

In addition, the Company continues to enroll patients in a two-stage Phase II trial of Pracinostat in combination with Vidaza in elderly patients with newly diagnosed acute myeloid leukemia (AML). If at any time three or more responses are observed in the first 27 patients, the trial will continue to enroll an additional 13 patients in the second stage, for a total of up to 40 evaluable patients. Preliminary data from this open-label trial is also anticipated by December 2014.

About Pracinostat

Pracinostat is an orally available HDAC inhibitor that has been tested in a number of Phase I and Phase II clinical trials in advanced hematologic disorders and solid tumor indications. Pracinostat has been generally well tolerated in more than 200 adult and pediatric patients to date, with readily manageable side effects that are often associated with drugs of this class, including fatigue. In a Phase I dose-escalation trial, Pracinostat demonstrated evidence of single-agent activity in
'/>"/>

SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
6. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
11. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... Forecast – Worldwide Analysis ... Market Analysis Insulin ...
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Oclaro, Inc. (NASDAQ: OCLR ), ... today outlined its complete line of fiber laser solutions ... a leading provider of diodes for industrial fiber laser ... operations, technology expertise and packaging technology to consistently deliver ...
... What:   Investigators from Northwestern ... 510(k) regulatory pathway—through which more than 90% of medical ... study is the most comprehensive survey to date about ... Devices and Radiological Health (CDRH) is currently weighing regulatory ...
Cached Medicine Technology:Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 2Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 3Findings From Largest Industry Assessment of 510(k) Process to be Released on May 24, 2011 2
(Date:7/9/2014)... signals active in almost all types of cancer sends ... may help fuel a tumour,s uncontrolled growth, new research ... London, identified a molecular trigger responsible for ratcheting up ... factory that makes the building blocks cancer cells need ... signalling pathway, called SREBP, controls the flow of messages ...
(Date:7/9/2014)... support cells and immune cells and the role ... development of diseases could open new therapeutic avenues ... conclusion of a review article by scientists from VIB ... . , Prof. Peter Carmeliet: "Consider the review article ... cells has been examined in minute detail for decades ...
(Date:7/9/2014)... users in Russia might contribute to HIV transmission ... by researchers from Boston University Schools of Medicine ... Pavlov State University, sought to discover the effect ... a cohort of HIV-positive people with lifetime of ... by police were more likely to share needlesincreasing ...
(Date:7/9/2014)... is available in French . ... 14 year old teens, including brain structure and function, personality, ... who will go on to develop binge drinking within the ... and other variables such as life events and a family ... drinking. Whether or not the child had had a ...
(Date:7/9/2014)... the world have been linked to an emerging ... the National Institute for Mathematical and Biological Synthesis ... contribute. , In a series of mathematical ... hemorrhage of internal organs in frogs, could cause ... they are exposed to the virus every few ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Wake-up call for more research into cell metabolism 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:What drives a child to abuse alcohol? 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2
... 80 Million Dogs in U.S. Households - One in ... TV news story on canine cancer by Fox,42 News, ... at http://www.kptm.com ),has generated emotional, heartfelt response and ... new treatments for dogs with cancer,as well as the ...
... of Rutgers University is one of 10 2008 Pew ... Pew Charitable Trusts. Launched in 1991, the Pew Latin ... trained Latin American scientists who show potential for stimulating ... as well as fostering collaboration between scientists in Latin ...
... Group,Inc. (Nasdaq: NYER ) announced that its ... Pharmacy Service Agreement with East Boston,Neighborhood Health Center ... period effective October 6, 2008. Under terms of ... each prescription dispensed in,exchange for providing comprehensive Clinical ...
... Costs for ... India, WEST BEND, Wis., Nov. 12 Anthem ... a new international medical,tourism pilot product that will allow ... designated facilities in India.,Beginning in January 2009, Anthem will ...
... - A novel protein marker has been found that ... regenerate injured liver tissue has the potential for cell-replacement ... of Pennsylvania School of Medicine led by Linda Greenbaum, ... Gastroenterology, have demonstrated that cells expressing the marker can ...
... or President should have an independent health examination to ensure ... today. , Lord David Owen, a trained doctor and ... people are affected by the decisions of people in high ... general public to ensure that their decision making is not ...
Cached Medicine News:Health News:Nyer Medical Group, Inc. Announces Pharmacy Service Agreement with East Boston Neighborhood Health Center 2Health News:Anthem Blue Cross and Blue Shield Introduces International Medical Tourism Pilot Program 2Health News:Anthem Blue Cross and Blue Shield Introduces International Medical Tourism Pilot Program 3Health News:Stem cells with potential to regenerate injured liver tissue identified by Penn researchers 2Health News:World leaders must be more open about their health 2
... 450,000 people in,the United States die ... a defibrillation shock,quickly during an episode ... that passes, the chance of,survival decreases ... Association,and JCAHO recommend that AEDs be ...
... female urinary stress incontinence (SUI) with a ... (BioArc™ SP) or a transobturator (BioArc™ TO) ... system combining synthetic and biologic materials. It ... The BioArc utilizes a polypropylene mesh for ...
... technology marries with the well-researched ... sling, for exceptional resultsby design. ... and host, reduces the potential ... or erosion and provides secure ...
Meets the demanding requirements of most pelvic floor reconstructive procedures, and is highly resistant to suture pull-through, demonstrating long-term durability, and serves as a structural support...
Medicine Products: